MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met
Zhenghui Hu(First Affiliated Hospital Zhejiang University), Liping Xie(First Affiliated Hospital Zhejiang University), Jian Wu(Sun Yat-sen University), Xianglai Xu(Fudan University), Xin Xu(Shanghai University of Sport), Hong Chen(Second Affiliated Hospital of Dalian Medical University), Shiqi Li(Zhejiang University), Yi Zhu(Zhejiang University), Xiangyi Zheng(Tianjin University), Yeqing Mao(First Affiliated Hospital Zhejiang University), Yiwei Lin(First Affiliated Hospital Zhejiang University)
Cited by 60
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276